+

WO2012113677A1 - Compositions probiotiques d'hydrate de carbone - Google Patents

Compositions probiotiques d'hydrate de carbone Download PDF

Info

Publication number
WO2012113677A1
WO2012113677A1 PCT/EP2012/052474 EP2012052474W WO2012113677A1 WO 2012113677 A1 WO2012113677 A1 WO 2012113677A1 EP 2012052474 W EP2012052474 W EP 2012052474W WO 2012113677 A1 WO2012113677 A1 WO 2012113677A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
composition according
resistant
vitamin
glucans
Prior art date
Application number
PCT/EP2012/052474
Other languages
German (de)
English (en)
Inventor
Günther Sawatzki
Richard ZELENKA
Original Assignee
Humana Milchunion Eg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humana Milchunion Eg filed Critical Humana Milchunion Eg
Priority to EP12710451.1A priority Critical patent/EP2699109A1/fr
Priority to EA201391205A priority patent/EA201391205A1/ru
Priority to CN201280009663.9A priority patent/CN103533851A/zh
Priority to UAA201311362A priority patent/UA109930C2/uk
Publication of WO2012113677A1 publication Critical patent/WO2012113677A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to carbohydrate compositions containing galacto-oligosaccharides and glucans having basic structures of al-4 and / or al-6-linked glucose units used in the preparation of prebiotic-type foods or pharmaceuticals.
  • Carbohydrates are used primarily to supply energy to the host organism.
  • scientific research has shown that some carbohydrates perform additional functions that support certain biological processes. These substances are also used as basic substances for functional foods.
  • foods and pharmaceuticals are increasingly being added to carbohydrates (so-called prebiotics) which have a prebiotic effect.
  • prebiotics is understood as influencing the bacterial colonization, in particular of the large intestine.
  • Prebiotics are characterized by the fact that they are not digested in the small intestine and thus reach the colon unabsorbed, where they are selectively digested by some bacteria and serve their diet.
  • prebiotic substances specifically support only those microorganisms which have beneficial effects on the host organism.
  • the intestinal flora is composed of several 1 00 bacterial species, the majority of which is present in the colon. At the same time, one only knows a selection of bacteria that can be detected outside the intestine. With modern DNA-based methods such. With metagenome analysis, one also tries to detect those bacteria about which so far very little is known. Nevertheless, classical bacteriological methods are still mainly used to detect the growth of bacteria and the suppression of pathogenic bacteria from stool sources in the laboratory.
  • Some prebiotic substances belonging to carbohydrates are primarily metabolized by so-called bifidobacteria and lactic acid bacteria (such as Lactobacillus acidophilus) in the colon.
  • these bacteria especially the bifidobacteria, selectively grow stronger than the other bacteria and in part suppress the growth of other bacteria, especially pathogenic bacteria. This is called a bifidogenic effect.
  • positive health effects such as the suppression of diseases, a better prosperity etc. on the host organism are discussed.
  • anti-pathogenic effects of prebiotics include a shorter duration of food in the intestine, a lowering of the cholesterol level, a less high glycemic response, an improvement in bone health (calcium absorption), one decreased energy intake, an improvement in the symptoms of chronic intestinal inflammation and a reduction in the risk of a disease of the intestinal cancer s.
  • glucans having a basic structure of glucose units connected to a 1 -4 and / or a 1-6 can be combined much better with galactooligosaccharides for a prebiotic composition.
  • the present invention therefore provides the use of a carbohydrate composition containing at least one galactooligosaccharide and at least one glucan having a basic structure of glucose units linked to al-4 and / or al-6 for the production of an agent having a prebiotic effect.
  • this glucan is a water-soluble glucan.
  • soluble carbohydrates are carbohydrates which form a homogeneous solution in the physical sense in water in a concentration of at least 1 g / L at room temperature (see Rompps Chemie Lexikon).
  • Prebiotic carbohydrates or prebiotics according to the invention and according to the internationally accepted definition indigestible, ie non-absorbable from the small intestine of healthy humans food ingredients that selectively stimulate the growth and / or activity of a bacterial species or a limited number of bacterial species and thus a health-promoting effect on the host organism (Roberfroid, MC; Prebiotics: prefential substrates for specific germs), at J Clin Nutr 73 (suppl): 406S-409S (2001)).
  • the invention is characterized in that in the combined use of galactooligosaccharides with glucans having a basic structure of al-4 and / or al-6 linked glucose units, a marked synergistic prebiotic effect occurs.
  • the glucans used according to the invention are oligosaccharides and / or polysaccharides having at least 3 D-glucose monomers which are linked to one another by a glycosidic bond, in this case by an .alpha.-glycosidic bond. These may each be contained singly or in a mixture of two or more glucans in the carbohydrate composition.
  • glucans are dextrans (al, 6-glucan + Glc branching (a-1,4 / 1,2 / 1,3)), mutans (a-1,6-glucan), glycogens (a-1,4- and ⁇ -1,6-glucan), pullulans ( ⁇ -1,4 and ⁇ , 6-glucan) and starches ( ⁇ -1,4 and ⁇ , 6-glucan (amylose, amylopectin)).
  • carbohydrate compositions contain starches.
  • the glucans used according to the invention are resistant starches, which in the Degradation of the resistant starches resulting degradation products and / or resistant Polydextrosen.
  • Resistant starches most preferably used are resistant maltodextrins and / or resistant dextrins.
  • Resistant starches are understood to mean substances formed chemically, like ordinary starches, and those resulting from the degradation of starch, which are normally not digestible, that is, which are not degradable by human digestive enzymes.
  • the resistant starches are therefore starches and starch-forming products that are not sorbed by the small intestine of healthy people and therefore belong to the fiber.
  • the resistant starches can be divided into four subspecies:
  • Type 1 physically inaccessible starches (for example, grains and plant components)
  • Type 2 native, granular starch with high crystallinity (for example from bananas)
  • Type 3 partially highly crystalline starches (boiled) generated by retrogradation (gelatinization)
  • Type 4 Chemically modified starches Of these so-called dietary fibers, positive effects are discussed by the corresponding bacteria, in particular by the formation of short-chain fatty acids as major end products of metabolism in the large intestine. These are the metabolites acetate, propionate and butyrate (D .L. Topping and P.M. Clifton; Short-chain fatty acids and human colonic function: Roles of resistant starch and non-starch polysaccharides; Physiol. Rev. 8 1: 103 1 - 1064 (2001)).
  • butyrate has beneficial effects on intestinal functions, in particular on the development of intestinal cells, by being used predominantly as an energy substrate of the host organism.
  • resistant starches The production of resistant starches is described, inter alia, for example in WO 2008/080630. This publication also contains further information on the molecular structure of resistant starches, on determination methods and on the sole use as a prebiotic dietary ingredient.
  • water-soluble maltodextrins are also available on the market. These include, for example, the products Nutrio se-FB and Nutriose-FM (from Roquette, with a degree of polymerization DP of approx.> 10) and the product Fibersol-2 (from ADM / Matsutani), without restricting the general.
  • water-soluble resitent dextrins / polydextroses are now available on the market. These include the products Litesse, Litesse-Two and Litesse-Ultra (by Danisco) and the product STA-LITE (by Töre & Lyle) (all with a DP degree of about> 12).
  • modified resistant starches to improve the microbial colonization of the digestive tract has been described for example in EP 0 910 359.
  • the prebiotic effect of resistant starch alone is well known.
  • a combination of carbohydrates using resistant starch as a prebiotic combined product is also described, for example, in WO 2005/056023.
  • the particularly effective prebiotic effect using the combination of galactooligosaccharides and resistant starches according to the invention has not been described anywhere.
  • the carbohydrate composition according to the invention contains no fructooligosaccharides.
  • the polydextroses are likely to specifically stimulate the bifidobacteria but not the lactobacilli (HM Probert, JHA Apaj alahti, N. Rautonen, J. Stowell, and GR Gibson; polydextrose, lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage continuous culture system; Appl.Environ.Microbiol. 70: 4505 - 45 1 1 (2004)) and selectively suppress bacteroid species.
  • lactobacilli HM Probert, JHA Apaj alahti, N. Rautonen, J. Stowell, and GR Gibson
  • polydextrose, lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage continuous culture system Appl.Environ.Microbiol. 70: 4505 - 45 1 1 (2004)
  • the galactooligosaccharides according to the invention are water-soluble, oligosaccharide carbohydrates having 3 to 9 monosaccharide units, preferably having 3 to 6 monosaccharide units, the monosaccharide being mainly galactose, in particular D-galactose.
  • the galactooligosaccharides are therefore preferably tri-tetra-, penta- or hexaoligosaccharides.
  • ⁇ -galacto-oligosaccharides may each be contained singly or in a mixture of two or more galactooligosaccharides in the carbohydrate composition. It is particularly preferred to use ⁇ -galacto-oligosaccharides or ⁇ -galacto-oligosaccharides. Very particular preference is given to using ⁇ -galactooligosaccharides.
  • Galacto-oligosaccharides are industrially produced using the enzyme beta-galactosidase by the so-called transglycosylation reaction. Therefore, they are also often referred to as transgalactooligosaccharides (TO S, TGO S).
  • galactooligosaccharides according to the invention are the commercially available products Oligomate (Yakult) and Vivinal-GO S (DOMO / Frieslandfoods).
  • Preferred mixtures for the prebiotic carbohydrate composition according to the invention contain 50-95% by weight of galactooligosaccharides and 5-50% by weight of .gtoreq.-4 and / or .alpha.-6 linked glucans.
  • Particularly preferred is a composition of 80-90% by weight of galactooligosac and 20-10% by weight of glucans with glucose units connected from od -4 and / or al -6.
  • Modified monomers can also be used for the carbohydrates used according to the invention. For example, it is possible to carry out enzymatic modification of galactooligosaccharides or glucans. Alternatively, it is also possible to make a technical modification. Further, the monomers or units constructed therefrom may also be modified by -O SO 3 H and / or -OPO 3 H groups.
  • a composition according to the invention consisting of 80% by weight galactooligosaccharides (Vivinal-GO S, DOMO / Frieslandfoods) and 20% by weight resistant maltodextrins (Nutriose-FM, Roquette) was compared to 100% galactooligosaccharides or 100% resistant Maltodextrins were tested as part of an infant formula at a concentration of 4g per liter in 240 infants aged 6-8 months in a clinical trial.
  • the clinical trial revealed that the composition of the present invention, the combination of galacto-oligosaccharides and resistant maltodextrins, had significantly more pronounced effects on the bacterial composition in the infant's stool compared to the same amount of each carbohydrate in the infant formula. Even with a doubling of the quantities In each case, the effect of the composition according to the invention could not be achieved.
  • compositions of the invention may be included in the following products: infant formulas for premature infants and normal-weight infants, infant and pediatric infants, clinical foods, pharmaceuticals, and dietetic foods.
  • the composition of the invention can make up a part of these products or replace conventional components.
  • existing carbohydrates can be partially replaced or supplemented by the composition.
  • lactose lactose
  • lactose lactose
  • the amount of the composition used according to the invention is adjusted according to age to specific daily amounts and the dosage form used.
  • infant formula and infant formula for infants between 3 and 20 g of the composition of the invention per day are presented.
  • Ratios may contain between 2-50 g of the composition of the invention per daily ration. This may be present as a component in both foods, dietetic foods, nutritional supplements, clinical foods and pharmaceuticals.
  • the compositions according to the invention can also be provided in combination with other constituents, both liquid, solid, as a powder, as a spray-dried powder, as emulsions, as compressed tablets or in the form of capsules.
  • composition according to the invention for various products is described below with reference to corresponding example formulations (all powder products) in detail.
  • advertising for the exemplary diets the indivi- dual ingredient lists and the ingredients listed as tables.
  • ingredients are prepared according to techniques well known to those skilled in the art, such as by mixing in the aqueous phase, homogenizing, pasteurizing, spray-drying and optionally dry-blending with the additional possibility of agglomerating the powders.
  • Baby milk formula The formula given is the basis for a so-called starter diet, ie for a baby born normal from birth
  • Skimmed milk 1 85 g demineralized whey powder 46, 7 g vegetable oils (contains soya ale-plant
  • Vitamin A vitamins 695 ⁇ g
  • the recipe given is the basis for a so-called follow-on milk 2, that is, for a diet that can be administered to normal-born infants after the 6th month.
  • Emulsifier soya lecithin 655 mg
  • Vitamin B12 0.54 ⁇
  • Vitamin B12 ⁇ g 1.50 0.21
  • a medicinal food is a food for sick infants, children and adults suffering from intestinal disorders (e.g., diarrhea).
  • the following recipe is given for such a healing diet, liquid form can be administered.
  • Vitamin D3 8.5 ⁇ g
  • Vitamin B12 0.49 ⁇ g

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une utilisation d'une composition d'hydrate de carbone pour la production d'un agent ayant une action probiotique, la composition contenant en tant qu'hydrates de carbone en plus de mono- et/ou disaccharides au moins un galactooligosaccharide et au moins un glucane ayant une structure de base à partir de motifs glucose reliés en α 1 -4 et/ou en α 1 -6.
PCT/EP2012/052474 2011-02-25 2012-02-14 Compositions probiotiques d'hydrate de carbone WO2012113677A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP12710451.1A EP2699109A1 (fr) 2011-02-25 2012-02-14 Compositions probiotiques d'hydrate de carbone
EA201391205A EA201391205A1 (ru) 2011-02-25 2012-02-14 Пребиотическая углеводная композиция
CN201280009663.9A CN103533851A (zh) 2011-02-25 2012-02-14 益生元糖类组合物
UAA201311362A UA109930C2 (uk) 2011-02-25 2012-02-14 Пребіотичні композиції вуглеводів

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011012494A DE102011012494A1 (de) 2011-02-25 2011-02-25 Prebiotische Kohlenhydrat-Zusammensetzungen
DE102011012494.2 2011-02-25

Publications (1)

Publication Number Publication Date
WO2012113677A1 true WO2012113677A1 (fr) 2012-08-30

Family

ID=45878904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/052474 WO2012113677A1 (fr) 2011-02-25 2012-02-14 Compositions probiotiques d'hydrate de carbone

Country Status (6)

Country Link
EP (1) EP2699109A1 (fr)
CN (1) CN103533851A (fr)
DE (1) DE102011012494A1 (fr)
EA (1) EA201391205A1 (fr)
UA (1) UA109930C2 (fr)
WO (1) WO2012113677A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103609748A (zh) * 2013-12-10 2014-03-05 内蒙古伊利实业集团股份有限公司 一种降血糖孕妇奶粉及其制备方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0910359A1 (fr) 1996-03-20 1999-04-28 The University Of New South Wales Selection et/ou renforcement de populations de micro-organismes residents dans le tractus gastro-intestinal
WO2000033854A1 (fr) * 1998-12-09 2000-06-15 N.V. Nutricia Preparation contenant des oligosaccharides et des probiotiques
EP1105002A2 (fr) 1998-08-11 2001-06-13 N.V. Nutricia Melanges d'hydrates de carbone
WO2005056023A1 (fr) 2003-12-12 2005-06-23 Nova Biotics As Produits de combinaison prebiotiques
WO2006134409A2 (fr) 2005-06-13 2006-12-21 Jaszberenyi Csaba Jozsef Compositions prebiotiques synergiques
EP1817964A1 (fr) * 2006-02-13 2007-08-15 Sweetwell NV Remplacement fonctionnel de sucre
WO2007098593A1 (fr) * 2006-03-03 2007-09-07 Health Beverage, Llc Boisson alcaline contenant des fibres et méthodes de production de ladite boisson
WO2008080630A1 (fr) 2006-12-29 2008-07-10 Bayer Cropscience Ag Amidon de maïs, et farines de maïs et produits alimentaires comprenant ledit amidon de maïs
WO2009075564A1 (fr) * 2007-12-10 2009-06-18 N.V. Nutricia Mélange de fibres pédiatriques
WO2010048481A1 (fr) * 2008-10-24 2010-04-29 Mead Johnson Nutrition Company Composition nutritionnelle destinée à promouvoir un développement sain et une croissance saine
US20100284980A1 (en) * 2009-05-11 2010-11-11 Rosales Francisco J Nutritional Composition To Promote Healthy Development And Growth
US20100316619A1 (en) * 2009-02-12 2010-12-16 Anja Wittke Nutritional composition with prebiotic component

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1898929A2 (fr) * 2005-07-05 2008-03-19 N.V. Nutricia Fraction de carbohydrate et utilisation de celle-ci pour une reponse au glucose postprandial plate
RU2462252C2 (ru) * 2006-03-10 2012-09-27 Н.В. Нютрисиа Применение неусвояемых сахаридов для лучшей адаптации младенцев после рождения
WO2008054193A1 (fr) * 2006-11-02 2008-05-08 N.V. Nutricia Produits alimentaires contenant des oligomères à base de saccharide
US20090118227A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0910359A1 (fr) 1996-03-20 1999-04-28 The University Of New South Wales Selection et/ou renforcement de populations de micro-organismes residents dans le tractus gastro-intestinal
EP1105002A2 (fr) 1998-08-11 2001-06-13 N.V. Nutricia Melanges d'hydrates de carbone
WO2000033854A1 (fr) * 1998-12-09 2000-06-15 N.V. Nutricia Preparation contenant des oligosaccharides et des probiotiques
WO2005056023A1 (fr) 2003-12-12 2005-06-23 Nova Biotics As Produits de combinaison prebiotiques
WO2006134409A2 (fr) 2005-06-13 2006-12-21 Jaszberenyi Csaba Jozsef Compositions prebiotiques synergiques
EP1817964A1 (fr) * 2006-02-13 2007-08-15 Sweetwell NV Remplacement fonctionnel de sucre
WO2007098593A1 (fr) * 2006-03-03 2007-09-07 Health Beverage, Llc Boisson alcaline contenant des fibres et méthodes de production de ladite boisson
WO2008080630A1 (fr) 2006-12-29 2008-07-10 Bayer Cropscience Ag Amidon de maïs, et farines de maïs et produits alimentaires comprenant ledit amidon de maïs
WO2009075564A1 (fr) * 2007-12-10 2009-06-18 N.V. Nutricia Mélange de fibres pédiatriques
WO2010048481A1 (fr) * 2008-10-24 2010-04-29 Mead Johnson Nutrition Company Composition nutritionnelle destinée à promouvoir un développement sain et une croissance saine
US20100316619A1 (en) * 2009-02-12 2010-12-16 Anja Wittke Nutritional composition with prebiotic component
US20100284980A1 (en) * 2009-05-11 2010-11-11 Rosales Francisco J Nutritional Composition To Promote Healthy Development And Growth

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
D.L. TOPPING; P.M. CLIFTON: "Short-chain fatty acids and human colonic function: Roles of resistant starch and nonstarch polysaccharides", PHYSIOL. REV., vol. 81, 2001, pages 1031 - 1064
H.M. PROBERT; J.H.A. APAJALAHTI; N. RAUTONEN; J. STOWELL; G.R. GIBSON: "Polydextrose, lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage continuous culture system", APPL.ENVIRON.MICROBIOL., vol. 70, 2004, pages 4505 - 4511, XP008066163, DOI: doi:10.1128/AEM.70.8.4505-4511.2004
MAKELAINEN H ET AL: "Synbiotic effects of galacto-oligosaccharide, polydextrose and Bifidobacterium lactis Bi-07 in vitro", INTERNATIONAL JOURNAL OF PROBIOTICS & PREBIOTICS, NEW CENTURY HEALTH PUBLISHERS, vol. 5, no. 4, 1 January 2010 (2010-01-01), pages 203 - 210, XP008152554, ISSN: 1555-1431 *
MORO G; MINOLI I; MOSCA M ET AL.: "Dosagerelated bifidogenic effects of galacto- and fructooligosaccharides in formula-fed term infants", J PEDIATR GASTROENTEROL NUTR, vol. 34, 2002, pages 291 - 295, XP008029577, DOI: doi:10.1097/00005176-200203000-00014
ROBERFROID, M.C: "Prebiotics: preferential substrates for specific germs?", AM J CLIN NUTR, vol. 73, 2001, pages 406S - 409S
S. FANARO; B. MARTEN; R. BAGNA; V. VIGI; C. FABRIS; L. PENA-QUINTANA; F. ARGUELLES; K. E. SCHOLZ-AHRENS; G. SAWATZKI; R. ZELENKA: "Galacto-oligosaccharides Are Bifidogenic and Safe at Weaning: A Double-blind Randomized Multicenter Study", JPGN, vol. 48, 2009, pages 82 - 88, XP009161038, DOI: doi:10.1097/MPG.0b013e31817b6dd2
Y. BOUHNIK; L. RASKINE; G. SIMONEAU ET AL.: "The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: double-blind, randomized, parallel-group, doseresponse relation study", AM. J. CLIN. NUTR., vol. 80, 2004, pages 1658 - 64

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103609748A (zh) * 2013-12-10 2014-03-05 内蒙古伊利实业集团股份有限公司 一种降血糖孕妇奶粉及其制备方法

Also Published As

Publication number Publication date
EP2699109A1 (fr) 2014-02-26
UA109930C2 (uk) 2015-10-26
DE102011012494A1 (de) 2012-08-30
EA201391205A1 (ru) 2014-02-28
CN103533851A (zh) 2014-01-22

Similar Documents

Publication Publication Date Title
DE60128395T2 (de) Ernährungszusammensetzung mit gesundheitsfördernder wirkung enthaltend oligosaccharide
EP1105002B1 (fr) Melanges d'hydrates de carbone
Whisner et al. Prebiotics, bone and mineral metabolism
DE60204058T2 (de) Netzwerk-bildende und pektin-enthaltende zubereitung
EP1267891B1 (fr) Glucides antiadhesifs
Tester et al. Glucomannans and nutrition
EP0957692B1 (fr) Melange d'hydrates de carbone
DE60215156T2 (de) Säurereguliertes viskoses ballaststoffsystem und seine verwendung
CA2991450C (fr) Utilisation de la polydextrose pour simuler les caracteristiques fonctionnelles des oligosaccharides du lait maternel, pour des bebes allaites artificiellement
DE69506095T2 (de) Diätfasern enthaltende Nahrungszusammensetzung
DE60221234T2 (de) Verwendung von füllstoffe als sättigungsmittel
EP2230943B1 (fr) Mélange nutritionnel à base de fibres pour patients pédiatriques
CN101945589A (zh) 用于改善肠道微生物群的非消化性碳水化合物的用途
DE60309169T2 (de) Verwendung vom pullulan als langsam verdauliches kohlenhydrat
TW201233334A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
DE69624243T2 (de) Verwendung von unverdaulichen oligosacchariden zur vorbeugung und behandlung von mittelohrentzündung bei menschen
DE60022513T2 (de) Verwendung eines fettsäure derivates in nasale gastrale enterale formulierungen
DE60217431T2 (de) Faserhaltiges Präparat zur enteralen Ernährung
EP2699109A1 (fr) Compositions probiotiques d'hydrate de carbone
EP4346450B1 (fr) Formule infantile destinée à l'alimentation des nourrissons recevant une formule infantile et du lait maternel humain
WO2023205762A9 (fr) Procédés et compositions pour ralentir le développement du diabète ou réduire un risque de diabète
DE19861497B3 (de) Babynahrung und ihre Verwendung zur Förderung der humanen Dickdarmflora
TW201244721A (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
KR20070049376A (ko) 다이어트 음료 조성물
DE19861508A1 (de) Kohlenhydratmischung

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12710451

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 201391205

Country of ref document: EA

REEP Request for entry into the european phase

Ref document number: 2012710451

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载